Skip to main content
Premium Trial:

Request an Annual Quote

Arnold Levine, George Adam, William Longfield, Mark Stevenson, Qun Zhou, Richard Taylor, David Chan, Johan de Bono, John Heymach, Peter Maimonis, Larry Oliver, Tim Bernard, Richard Broadhead

Life Technologies has appointed three former directors of Applied Biosystems to its board, following the merger last month of ABI with Invitrogen: Arnold Levine, George Adam, and William Longfield.
Levine will serve on the board’s Science and Technology Committee, Adam will serve on the Audit Committee, and Longfield will be on the Compensation and Organizational Committee.
In addition, as previously announced, Life Technologies appointed Mark Stevenson, formerly the president and COO of ABI, to the position of president and COO of the combined firm.
The company disclosed in an SEC filing last week that Stevenson will receive an annual salary of $650,000 with options to purchase up to $3.6 million in shares. He will also receive a cash payment of $6,798,040 related to the termination of his employment agreement with ABI.

Vermillion said this week in a document filed with the US Securities and Exchange Commission that Qun Zhou has been appointed interim CFO, effective Nov. 26.
She had previously been interim CFO of the company between November 2007 and Aug. 26, 2008. Zhou has been corporate controller since February 2007.
Before joining Vermillion, she was controller of ViOptix. Before that she was business unit controller with Philips Medical Systems.
Zhou replaces Richard Taylor who had served as interim CFO and senior finance consultant since Aug. 26. He and the company mutually agreed not to renew the consulting agreement, which expired on Nov. 26, the company said.

Decision Biomarkers this week announced the formation of its scientific advisory board. Its members include David Chan, Johan de Bono, John Heymach, Peter Maimonis, and Larry Oliver.
Chan is the director of the Center for Biomarker Discovery and director of the clinical chemical division at Johns Hopkins Medical Institution. De Bono is a senior lecturer at the Institute for Cancer Research, Royal Marsden Hospital, where he leads the prostate cancer team. He also directs the clinical drug development Phase I trial program at Royal Marsden Hospital.
Heymach is an assistant professor of thoracic head/neck medical oncology at the University of Texas MD Anderson Cancer Center. Maimonis is vice president of biological research at Decision Biomarkers. And Oliver is scientific director of Mayo clinical trial services and director of the metals laboratory in the department of laboratory medicine and pathology at Mayo Clinic.

Oxford Expression Technologies this week announced the appointments of Tim Bernard as business development manager and Richard Broadhead as sales manager.
Bernard has 24 years of experience in executive leadership with life sciences, the company said in a statement. He previously was the CEO of consulting firm Pivotal Scientific and was managing director at both AbD Serotec and Morphosys. He is also an investor in the OET’s second round of financing, which the company said this week was completed.
Broadheadhas “significant” global sales and marketing experience and was previously at Invitrogen and Flowgen, OET said.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.